Anti-MYH13 Polyclonal Antibody for WB, IF-P, ELISA - Q9UKX3

Core Product Specifications and Parameters

Biological Background: Myosin-13 Function and Localization

• Myosin-13, also known as MyHC-eo or MyHC-IIL, is a fast-twitch myosin heavy chain predominantly expressed in specific striated muscles.
• It mediates high-velocity, low-tension contractions, enabling rapid movements in extraocular and laryngeal muscles.
• The protein localizes to the cytoplasm as a component of the myofibril thick filament, where it interacts with actin and ATP to generate mechanical force.
• Tissue specificity is restricted to extraocular and laryngeal muscles, as identified by transcript and protein profiling.
• Key features include N-terminal motor domain with actin- and ATP-binding sites, a neck region with calmodulin-binding IQ motifs, and a C-terminal coiled-coil rod domain for dimerization.
• Post-translational modifications such as methylation have been detected by proteomics, potentially modulating protein interactions or stability.
• The predicted molecular mass is approximately 224 kDa, consistent with UniProt annotation (223.6 kDa).

Experimental Guidance and Technical Tips

• The immunogen spans residues 1240–1320 in the C-terminal coiled-coil domain; polyclonal antibodies may also recognize splice isoforms or related myosins—validate specificity using MYH13-positive lysates (e.g., extraocular muscle).
• For Western blot, use 6–8% SDS-PAGE gels and prolong transfer (e.g., overnight at low voltage) to efficiently transfer the ~224 kDa protein; include a high-molecular-weight marker.
• In immunofluorescence (IF-P), consider co-staining with a sarcomeric marker (e.g., α-actinin) to confirm myofibril localization in mouse or rat tissue sections, as cross-reactivity is indicated.
• ELISA performance should be assessed with the recombinant immunogen as a positive control; due to the restricted expression, native tissue lysates may require sensitivity optimization.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio empowers diagnostic manufacturers, laboratories, and research institutes by streamlining access to IVD raw materials, technical services, and consulting—from concept to clinic. This anti-MYH13 polyclonal antibody supports studies in muscle physiology and potential biomarker development for disorders affecting extraocular or laryngeal muscles. As a comprehensive sourcing partner, CamelBio offers validated antibody pairs, optimized polyclonal antibodies, bulk ancillary reagents, and customized procurement for rare-target raw materials, ensuring seamless integration into your diagnostic or research pipeline.